Technical Analysis for AZRX - AzurRx BioPharma, Inc.

Grade Last Price % Change Price Change
grade F 1.04 -3.70% -0.04
AZRX closed down 3.7 percent on Wednesday, August 21, 2019, on 2.3 times normal volume.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical AZRX trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.70%
New Uptrend Bullish -3.70%
BB Squeeze Ended Range Expansion -3.70%
Above Upper BB Strength -3.70%
Up 3 Days in a Row Strength -3.70%
Upper Bollinger Band Touch Strength -3.70%

Older signals for AZRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:
Profile
Azurrx Biopharma, Inc. is a biopharmaceutical company. It focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's product pipeline consists of MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency and AZX1101, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. Azurrx Biopharma, Inc. is headquartered in New York City.
Biotechnology Biopharmaceutical Life Sciences Biology Molecular Biology Insulin Gastrointestinal Diseases Synthetic Biology Exocrine Pancreatic Insufficiency Recombinant Dna Treatment Of Gastrointestinal Diseases
Is AZRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 13 AzurRX Biopharma EPS misses by $0.03
Aug 13 AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 25 Dosing underway in mid-stage CF study of Proteostasis combo therapies
Jul 23 AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock
Jul 18 NFLX, SAP among premarket losers
Jul 18 AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock
Jul 17 AzurRx readies stock offering; shares down 4% after hours
Jul 17 AzurRx BioPharma Announces Proposed Public Offering of Common Stock
Jul 16 Microcaps mostly among midday movers
Jul 10 AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI
See more AZRX news...
Indicators
Indicator Value
52 Week High 3.75
52 Week Low 0.86
Average Volume 233,544
200-Day Moving Average 1.9238
50-Day Moving Average 1.2634
20-Day Moving Average 1.0062
10-Day Moving Average 1.0015
Average True Range 0.0882
ADX 25.42
+DI 24.7062
-DI 19.5023
Chandelier Exit (Long, 3 ATRs ) 0.8954
Chandelier Exit (Short, 3 ATRs ) 1.1246
Upper Bollinger Band 1.0737
Lower Bollinger Band 0.9387
Percent B (%b) 0.75
BandWidth 13.416816
MACD Line -0.0656
MACD Signal Line -0.0986
MACD Histogram 0.033
Fundamentals Value
Market Cap 11.68 Million
Num Shares 11.2 Million
EPS -1.64
Price-to-Earnings (P/E) Ratio -0.63
Price-to-Sales 0.00
Price-to-Book 7.63
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.25
Resistance 3 (R3) 1.27 1.21 1.22
Resistance 2 (R2) 1.21 1.16 1.21 1.20
Resistance 1 (R1) 1.13 1.13 1.10 1.11 1.19
Pivot Point 1.07 1.07 1.06 1.07 1.07
Support 1 (S1) 0.99 1.02 0.96 0.97 0.89
Support 2 (S2) 0.93 0.99 0.93 0.88
Support 3 (S3) 0.85 0.93 0.87
Support 4 (S4) 0.83